Nanjing Vishee Medical Technology Co., Ltd
Sembol: 688580.SS
SHH
47.44
CNYBugünkü piyasa fiyatı
25.8198
F/K Oranı
0.0000
PEG Oranı
3.23B
MRK Kapağı
- 0.01%
DIV Verimi
Nanjing Vishee Medical Technology Co., Ltd (688580-SS) Finansal Tablolar
Bilanço
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1155 | 1248.1 | 1366 | ||||||||||
balance-sheet.row.short-term-investments | 0 | 2266.4 | 0 | 0 | ||||||||||
balance-sheet.row.net-receivables | 0 | 47.3 | 31.9 | 36.7 | ||||||||||
balance-sheet.row.inventory | 0 | 39.9 | 34.8 | 30.4 | ||||||||||
balance-sheet.row.other-current-assets | 0 | 12.6 | 4.3 | 1.2 | ||||||||||
balance-sheet.row.total-current-assets | 0 | 1254.8 | 1319.2 | 1434.3 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 321.5 | 172.5 | 100.3 | ||||||||||
balance-sheet.row.goodwill | 0 | 69.3 | 69.3 | 0 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 120.6 | 106.5 | 18.8 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 189.9 | 175.8 | 18.8 | ||||||||||
balance-sheet.row.long-term-investments | 0 | -2244.3 | 0 | 0.8 | ||||||||||
balance-sheet.row.tax-assets | 0 | 15.1 | 7.9 | 12.7 | ||||||||||
balance-sheet.row.other-non-current-assets | 0 | 2269 | 8.8 | 71.9 | ||||||||||
balance-sheet.row.total-non-current-assets | 0 | 551.2 | 365 | 204.4 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 0 | 1806 | 1684.2 | 1638.7 | ||||||||||
balance-sheet.row.account-payables | 0 | 18 | 19.7 | 9.3 | ||||||||||
balance-sheet.row.short-term-debt | 0 | 0 | 1.2 | 1.2 | ||||||||||
balance-sheet.row.tax-payables | 0 | 19.6 | 21.1 | 29.3 | ||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 1.8 | ||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 0 | 133.7 | 94.8 | 1.6 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 27.6 | 26.4 | 1.8 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 1.2 | 1.8 | ||||||||||
balance-sheet.row.total-liab | 0 | 179.3 | 155.7 | 105.7 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0 | 68.6 | 68.6 | 68.3 | ||||||||||
balance-sheet.row.retained-earnings | 0 | 438.4 | 349.1 | 344.3 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 1588.9 | 34.8 | 58.1 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | -469.2 | 1076 | 1062.3 | ||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 1626.8 | 1528.5 | 1533.1 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 1806 | 1684.2 | 1638.7 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | 0 | 1626.8 | 1528.5 | 1533.1 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||
Total Investments | 0 | 22 | 0 | 0.8 | ||||||||||
balance-sheet.row.total-debt | 0 | 0 | 1.2 | 3 | ||||||||||
balance-sheet.row.net-debt | 0 | -1155 | -1246.9 | -1363 |
Nakit Akış Tablosu
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 93.8 | 177.5 | 143.1 | |||||||||
cash-flows.row.depreciation-and-amortization | 0 | 17.1 | 11.1 | 8.8 | |||||||||
cash-flows.row.deferred-income-tax | 0 | 2.3 | -8.1 | -1.1 | |||||||||
cash-flows.row.stock-based-compensation | 0 | -2.8 | 21.4 | 1.1 | |||||||||
cash-flows.row.change-in-working-capital | 0 | -8.7 | -33.5 | -19.1 | |||||||||
cash-flows.row.account-receivables | 0 | 7.3 | -13.1 | -15.9 | |||||||||
cash-flows.row.inventory | 0 | 1.8 | 6.7 | -5.6 | |||||||||
cash-flows.row.account-payables | 0 | -20.1 | -19 | 3.4 | |||||||||
cash-flows.row.other-working-capital | 0 | 2.3 | -8.1 | -1.1 | |||||||||
cash-flows.row.other-non-cash-items | 0 | -15.6 | -11 | -12.1 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -95.6 | -87.3 | -11.7 | |||||||||
cash-flows.row.acquisitions-net | 0 | -34.2 | 0 | 11.7 | |||||||||
cash-flows.row.purchases-of-investments | 0 | -3648 | -4264 | -2102.4 | |||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 3664 | 4284.6 | 2115.8 | |||||||||
cash-flows.row.other-investing-activites | 0 | 9 | -10 | -11.7 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -104.8 | -76.8 | 1.9 | |||||||||
cash-flows.row.debt-repayment | 0 | -2 | -1.3 | -14 | |||||||||
cash-flows.row.common-stock-issued | 0 | 16.9 | -0.3 | -18 | |||||||||
cash-flows.row.common-stock-repurchased | 0 | -14.9 | 1.6 | 18 | |||||||||
cash-flows.row.dividends-paid | 0 | -88.9 | -71.8 | -50.3 | |||||||||
cash-flows.row.other-financing-activites | 0 | -6.1 | -9.2 | 1059.1 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -95 | -81 | 994.8 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.net-change-in-cash | 0 | -113.6 | -0.4 | 1117.4 | |||||||||
cash-flows.row.cash-at-end-of-period | 0 | 1247.7 | 1361.3 | 1361.7 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 1361.3 | 1361.7 | 244.4 | |||||||||
cash-flows.row.operating-cash-flow | 0 | 86.2 | 157.4 | 120.8 | |||||||||
cash-flows.row.capital-expenditure | 0 | -95.6 | -87.3 | -11.7 | |||||||||
cash-flows.row.free-cash-flow | 0 | -9.4 | 70 | 109.1 |
Gelir Tablosu Satırı
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 462.2 | 321.6 | 430 | ||||||||||
income-statement-row.row.cost-of-revenue | 0 | 130.5 | 88.5 | 108.5 | ||||||||||
income-statement-row.row.gross-profit | 0 | 331.7 | 233.1 | 321.6 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 0 | 1.6 | 18 | 7.4 | ||||||||||
income-statement-row.row.operating-expenses | 0 | 208.7 | 162.9 | 163.1 | ||||||||||
income-statement-row.row.cost-and-expenses | 0 | 339.2 | 251.4 | 271.6 | ||||||||||
income-statement-row.row.interest-income | 0 | 19.3 | 19.3 | 16.8 | ||||||||||
income-statement-row.row.interest-expense | 0 | 1.3 | 0.3 | 0.2 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 1.6 | 1.4 | 2.7 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 0 | 1.6 | 18 | 7.4 | ||||||||||
income-statement-row.row.total-operating-expenses | 0 | 1.6 | 1.4 | 2.7 | ||||||||||
income-statement-row.row.interest-expense | 0 | 1.3 | 0.3 | 0.2 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 20.1 | 19.5 | 14.9 | ||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.operating-income | 0 | 148.4 | 104.5 | 194.7 | ||||||||||
income-statement-row.row.income-before-tax | 0 | 150 | 105.8 | 197.4 | ||||||||||
income-statement-row.row.income-tax-expense | 0 | 13.8 | 12 | 19.8 | ||||||||||
income-statement-row.row.net-income | 0 | 136.3 | 93.8 | 177.8 |
Sıkça Sorulan Sorular
Nedir Nanjing Vishee Medical Technology Co., Ltd (688580.SS) toplam varlıklar?
Nanjing Vishee Medical Technology Co., Ltd (688580.SS) toplam varlıklar 1806024041.000 şeklindedir.
İşletmenin yıllık geliri nedir?
Yıllık gelir N/A'dur.
Firma kâr marjı nedir?
Firma kar marjı 0.715'dir.
Şirket serbest nakit akışı nedir?
Serbest nakit akışı -0.334'dur.
İşletme net kar marjı nedir?
Net kâr marjı 0.282'dir.
Firma toplam geliri nedir?
Toplam gelir 0.306'dur.
Nedir Nanjing Vishee Medical Technology Co., Ltd (688580.SS) net kar (net gelir)?
Net kar (net gelir) 136258629.000'dur.
Firmanın toplam borcu nedir?
Toplam borç 0.000'dir.
Faaliyet giderleri rakamı nedir?
İşletme giderleri 208672734.000'dır.
Şirket nakit rakamı nedir?
İşletme içi nakit 0.000'tir.